# Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Source: https://onco.cc/trials/nct05945823/  
OnCo record `nct05945823` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Futibatinib, Pembrolizumab, Cisplatin and Oxaliplatin in oesophageal cancer and pancreatic ductal adenocarcinoma, run by Taiho Oncology, Inc., active and no longer recruiting.

## Summary

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors is a phase 2 interventional study registered as NCT05945823 by Taiho Oncology, Inc., with 53 participants enrolled, started 2023-07-13 and due to reach its primary completion in 2026-10-01. Interventions recorded: Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin and Leucovorin.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05945823
- Phase: 2
- Setting: A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.
- Sponsor: Taiho Oncology, Inc.
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT05945823: https://clinicaltrials.gov/study/NCT05945823

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Araris Biotech (Taiho)](https://onco.cc/companies/araris/)

---
JSON: https://onco.cc/api/v1/entities/nct05945823.json